You are here

P&T® Journal contents for December 2007

Features

In a comparison of two erythropoiesis-stimulating agents, drug costs were found to be lower for epoetin alfa than for darbepoetin alfa.
John J. Barron, PharmD, W. Daniel Grochulski, PhD, Samir H. Mody, PharmD, MBA, Brahim K. Bookhart, MBA, MPH, and R. Scott McKenzie, MD
Analysis and Opinion
Although far from perfect, the FDA Amendments Act gives the FDA more funds and authority, for example, in overseeing drug distribution and in forcing manufacturers to provide drug guides and to perform post-approval safety trials.
Stephen Barlas
Commentary
There won’t be any juicy industry gossip or corporate intrigue, but Johnson & Johnson and GlaxoSmithKline hope that their new blogs will at least set the record straight about their companies and products.
Miriam Reisman
Meeting Highlights
Topics include galiximab, bendamustine, and rituximab for hematological malignancies; pazopanib for renal cell cancer; trastuzumab and lapatinib for breast cancer; sorafenib/temozomide for melanoma; and IRX-2 for head and neck cancer
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Presentations cover advances in therapies for breast, prostate, and renal cancers and melanoma; adalimumab for patients with Crohn’s disease and fistula; and infliximab for the treatment of ulcerative colitis and colectomy.
Walter Alexander
Notice how we haven’t aged a bit in five years!

Departments

Editorial
David Nash, MD, MBA, explains how a new initiative encourages the participation of previously underrepresented groups in clinical trials, including the elderly, minorities, and rural residents.
David B. Nash, MD, MBA
Prescription: Washington
Stephen Barlas discusses the Community Pharmacy Fairness Act, which might help independent pharmacies in their struggle to compete for customers being forced to use mail-order programs.
Stephen Barlas
Medication Errors
In Part 1 of a two-part series, Matthew Grissinger, RPh, FASCP, describes the factors that often contribute to the problem of unsafe patient-controlled analgesia.
Matthew Grissinger, RPh, FASCP
From Abilify to Trasylol, P&T presents the latest information on FDA approvals, new indications, and industry updates.
Drug Forecast
The authors review selegiline orally disintegrating tablets (Zelapar) for Parkinson’s diseas­e.
Marilena S. Antonopoulos, PharmD, and Kristine S. Kim, PharmD